ESH AL 2018 | Combining existing drugs for the creation of novel AML therapies

Gail Roboz

Gail Roboz, MD, from the Weill Medical College of Cornell University, New York City, NY, explores exciting next-generation agents for the treatment of acute myeloid leukemia (AML), such as guadecitabine, a next-generation DNA hypomethylating agent that has the potential to be more effective than decitabine. A similar concept has previously been used for the development of the CPX-351, a liposomal formulation of cytarabine and daunorubicin, which received FDA approval for the treatment of high-risk AML. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Share this video